Skip to main content
  • Saved

from Pathologist Connect made a Post

Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.

Adagrasib Demonstrates Favorable Efficacy, Pharmacokinetic Profile in Advanced KRAS G12C+ NSCLC

Adagrasib Demonstrates Favorable Efficacy, Pharmacokinetic Profile in Advanced KRAS G12C+ NSCLC

Source :

https://www.onclive.com/view/adagrasib-demonstrates-favorable-efficacy-pharmacokinetic-profile-in-advanced-kras-g12c-nsclc

Adagrasib (MRTX849) yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C-mutant advanced non-small cell lung cancer, according to updated findings of the phase 1/1b/2 KRYSTAL-1 study that were presented during the 2021 European Lung Cancer Conference .